CT, an enterotoxin secreted by Vibrio cholerae that is responsible for the diarrhea associated with cholera, is a potent mucosal adjuvant for stimulating antigen-specific responses when administered by a nasal or oral route [1] [2] [3] . CT is a hexameric protein complex composed of five B subunits that bind to the cell surface GM1 ganglioside receptor and one catalytic A subunit that activates the heterotrimeric guanine-nucleotidebinding protein G sα , which in turn stimulates cyclic AMP (cAMP) production by adenylate cyclase 1,4,5 . Several studies have linked the adjuvant effect of CT to the catalytic a ctivity of the monomeric A subunit and the ADP ribosylation of G s 4,5 . Although the toxicity of CT prevents its implementation in the clinic, understanding the mechanisms underlying its potent adjuvant activity may lead to the development of nontoxic and effective adjuvants for mucosal vaccination.
of CT, mice were intranasally treated with a cocktail of antibiotics (ampicillin, neomycin, metronidazole and vancomycin) once 1 week before immunization, followed by administration of the same antibiotic cocktail in the drinking water ad libitum for 3 weeks. The treatment resulted in a depletion of bacteria, including a >500-fold decrease of cultivatable bacteria in the nasal lavage fluid (NALF) 2 weeks after immunization (data not shown). Antibiotic-treated and untreated mice were intranasally immunized with the model antigen human serum albumin (HSA) and CT, and 2 weeks later sera were collected and analyzed for HSA-specific IgG, using ELISA. As expected, no antigen-specific IgG was detected in the plasma of mice that had been immunized with HSA in the absence of CT (Supplementary Fig. 1 ), whereas mice that had been immunized with HSA and CT showed a robust antigen-specific IgG response (Fig. 1a) . The depletion of bacteria by antibiotic treatment in mice suppressed the production of HSA-specific IgG as compared to that in untreated mice (Fig. 1a) . After ex vivo restimulation of splenocytes with antigen, production of the T H 1 cytokine interferon (IFN)-γ and the T H 2 cytokine IL-5 were increased in splenocytes from untreated mice but not in splenocytes from antibiotic-treated mice (Fig. 1b) .
To examine the contribution of the microbiota in mucosal immunization via a different route, we performed oral immunization with HSA and CT in antibiotic-treated and untreated mice. Similarly to the results we observed with nasal immunization, bacterial depletion impaired the induction of HSA-specific IgG in plasma, as well as the production of IL-5 and IFN-γ by restimulated splenocytes, in mice that were orally immunized with HSA and CT ( Supplementary  Fig. 2 ). In contrast, intraperitoneal immunization with HSA and CT induced comparable antigen-specific IgG responses in antibiotictreated and untreated mice (Supplementary Fig. 3 ). To assess whether symbiotic bacteria regulate antigen-specific IgG responses induced by other adjuvants, we immunized antibiotic-treated and untreated mice intranasally with HSA and either the oligodeoxynucleotide TLR9 agonist CpG or the TLR2 agonist MALP-2 (a lipoprotein derived from Mycoplasma), instead of CT, in antibiotic-treated and untreated mice. Treatment with antibiotics reduced the production of HSA-specific IgG when CpG was used as adjuvant, but there was a minimal effect in mice treated with MALP-2 ( Supplementary Fig. 4 ). These results suggest that the route of immunization is important for the ability of the microbiota to enhance the adjuvant activity of CT. Furthermore, the microbiota can enhance the adjuvant activity of some but not all adjuvants in the nasal cavity. To confirm a role for symbiotic bacteria in the mucosal adjuvanticity of CT, we intranasally immunized specific-pathogen-free (SPF) and GF mice with HSA and CT. We found that primary and secondary HSA-specific IgG responses were impaired in GF mice as compared to those in SPF mice harboring a microbiota (Fig. 1c,d) . Furthermore, the production of IFN-γ and IL-5 that was induced by restimulating splenocytes with antigen ex vivo was abrogated in splenocytes from GF mice (Fig. 1e) . These results indicate that symbiotic bacteria have a role in promoting the adjuvant activity of CT after intranasal immunization.
Nod2 and Ripk2 mediate the adjuvant activity of cholera toxin Bacteria are sensed by host PRRs, including TLRs and NLRs, which leads to the induction of immune responses 14, 23, 24 . To assess which PRRs may be involved in the recognition of bacteria during intranasal immunization with CT, we intranasally immunized wild-type (WT) mice, mice deficient in myeloid differentiation primary response gene 88 (Myd88; an adaptor involved in signaling via the TLRs, the IL-1 receptor (IL-1R) and the IL-18 receptor (IL-18R)) and mice lacking Ripk2 (the adaptor required for Nod1 and Nod2 signaling 14, 23 ). Ripk2 −/− mice, but not Myd88 −/− mice, had impaired induction of HSA-specific IgG responses after intranasal immunization with CT (Fig. 2a,b) . Because Ripk2 mediates both Nod1 and Nod2 signaling, we next tested the ability of CT to promote production of antigenspecific IgG in Nod1 −/− or Nod2 −/− mice. The antigen-specific IgG responses induced by nasal immunization with HSA and CT were impaired in Nod2 −/− mice but not in Nod1 −/− mice ( Fig. 2c-e) . The amounts of HSA-specific IgG1, IgG2b and IgM were also reduced in Nod2 −/− mice after intranasal immunization with HSA and CT (Supplementary Fig. 5) . Furthermore, the production of IFN-γ and IL-5 induced by restimulation of splenocytes with antigen was (Fig. 2f) . When mice were intranasally immunized with higher amounts of HSA and CT, HSA-specific IgG responses were still reduced in Nod2 −/− mice, as compared to those in WT mice (Supplementary Fig. 6a ). Moreover, HSA-specific IgA production in the nasal cavity was also reduced in Nod2 −/− mice ( Supplementary Fig. 6b ). In contrast, Ripk2 −/− and Nod2 −/− mice mounted normal antigen-specific IgG responses after they were immunized intraperitoneally with HSA and either CT or alum, respectively ( Supplementary Fig. 7 ), indicating that Nod2 and Ripk2 contribute to CT adjuvanticity only via mucosal sites. DCs have a role in promoting the adjuvant activity of CT 13 . Analyses of cells in the nasal-associated lymphoid tissue (NALT) showed that the phagocytic CD45 + CD11c + cell population expressed greater amounts of Nod2 mRNA than the CD45 + CD11c − or CD45 − CD11c − cell populations (Supplementary Fig. 8 ), suggesting that CD11c + DCs or macrophages could play a role in response to a Nod2 agonist.
To determine whether Nod2 has a role within phagocytes, including DCs, we immunized control mice and Itgax-Cre;Nod2 fl/fl mice, in which Nod2 was deleted in CD11c + cells (Supplementary Fig. 9 ). HSA-specific IgG responses were impaired in Itgax-Cre;Nod2 fl/fl mice after intranasal immunization with CT ( Fig. 2g) . In contrast, HSA-specific IgG production in response to immunization with CT was not altered in Krt14-Cre;Nod2 fl/fl mice, in which Nod2 is deleted in epithelial cells expressing the keratin 14 gene ( Supplementary  Fig. 10 ). These results indicate that Nod2 has a role within CD11c + phagocytes to promote the adjuvant activity of CT.
Nod2 is required for the generation of T FH cells and plasma cells
T FH cells mediate the generation and maintenance of germinal centers, as well as the survival and selection of B cells that differentiate into plasma cells capable of producing high-affinity antibodies to foreign antigens [25] [26] [27] . Because Nod2 was important for antigen-specific IgG production, we examined whether Nod2 regulates the generation of T FH cells and plasma cells after intranasal immunization with CT. The percentage and total number of T FH cells (CXCR5 + PD-1 hi ) and plasma cells (CD19 + CD138 + IgD − ) were reduced in the draining lymph nodes of Nod2 −/− mice that were immunized intranasally with CT and HSA, as compared to those in WT mice ( Fig. 3a-f) . Furthermore, enzyme-linked immunospot (ELISPOT) assays revealed that Nod2 deficiency decreased the number of cells producing HSAspecific IgG in the draining lymph nodes of immunized mice (Fig. 3g) .
These results indicate that Nod2 regulates the generation of T FH cells and plasma cells after intranasal immunization with CT.
Cholera toxin enhances Nod2-induced cytokine production in DCs Pretreatment of DCs with CT inhibits the ability of DCs to produce cytokines in response to TLR agonists such as lipopolysaccharide 8, 11 .
To determine whether CT regulates Nod2-induced cytokine production, we treated DCs with CT in the presence or absence of the Nod2 agonist MDP. Treatment with CT enhanced MDP-induced production of IL-6, IL-23 and the p40 subunit of the IL-12 heterodimer (IL-12p40) in DCs (Fig. 4a) , and this required Nod2 (Fig. 4a) and Ripk2 (Fig. 4b) . Thus, CT enhances Nod2-induced cytokine production in DCs.
Cholera toxin enhances Nod2 activation via cAMP and PKA CT activates adenylate cyclase, resulting in increased concentrations of intracellular cAMP 1, 5 . To determine whether cAMP regulates Nod2-induced cytokine production, we treated DCs with the cellpermeable cAMP analog 8-bromo-cAMP (8-Br-cAMP), in the absence or presence of MDP. As observed with CT, 8-Br-cAMP treatment enhanced the secretion of IL-6, IL-23 and IL-12p40 in the presence of MDP (Fig. 5a) . Moreover, treatment with CT or cAMP enhanced the expression of Nod2 mRNA in DCs (Supplementary Fig. 11 ).
The effects of increased intracellular cAMP are mediated by protein kinase A (PKA) and the Rap guanine nucleotide exchange factors Rapgef3 (also known as exchange protein directly activated by cAMP (Epac) 1) and Rapgef4 (also called Epac2) 7, 12 . To clarify the pathway involved in the regulation of MDP-induced responses by treatment with CT, DCs were treated with specific activators of each pathway together with MDP. Cotreatment with MDP and N 6 -benzoyl-cAMP, an activator of PKA, enhanced cytokine production, whereas treatment with MDP and 8-CPT-2′-O-Me-cAMP, an activator of Epac, did not (Fig. 5b) . These results suggest that CT enhances Nod2-induced cytokine production via a cAMP-and PKA-dependent mechanism in DCs 28 .
Nod2-stimulatory bacteria boost the adjuvanticity of cholera toxin To test whether MDP can mediate the adjuvant activity of CT in the absence of a microbiota, we immunized GF mice intranasally with HSA in the presence of MDP, CT or both and then measured HSA-specific IgG responses after intranasal stimulation. The combination of MDP and CT induced a robust antigen-specific IgG response, but treatment with MDP or CT alone did not (Fig. 6a) . There was a marginal increase in the amount of HSAspecific IgG in GF mice stimulated with CT than in mice stimulated with MDP alone (Fig. 6a) , suggesting that CT can induce small amounts of antigenspecific IgG in the absence of the microbiota.
We next assessed the presence of Nod2-stimulatory activity in the NALF by using a reporter assay 29 and detected Nod2-stimulatory activity in the NALF from SPF mice (Fig. 6b) . These experiments suggested that the nasal cavity is inhabited by bacteria that produce peptidoglycan molecules containing MDP. To identify the bacteria that produce molecules with Nod2-stimulatory activity, we isolated bacterial colonies from the NALF of mice and analyzed individual bacterial colonies for Nod2-stimulatory activity and for their taxa by 16S RNA gene sequencing. Some bacterial species isolated from the nasal cavity (including S. sciuri and Bacillus clausii) showed robust Nod2-stimulatory activity, whereas others (including Bordetella hinzii, Staphylococcus gallinarum and Bacillus pumilus) stimulated less Nod2 activity (Fig. 6c) . To compare the contribution of bacteria possessing high or low Nod2-stimulatory activity to the adjuvanticity of CT, we intranasally inoculated SPF mice with live S. sciuri or S. gallinarum, together with HSA and CT. Colonization of the nasal cavity of mice with S. sciuri, which exhibited robust Nod2-stimulatory activity, enhanced the antigen-specific IgG response after immunization with HSA and CT, whereas colonization with S. gallinarum induced little or no significant adjuvant activity ( Fig. 6d and Supplementary  Fig. 12) . Furthermore, monocolonization of the nasal cavity of GF mice with S. sciuri enhanced the adjuvanticity of CT (Fig. 6e) . To test whether bacteria can function locally, we inoculated the nasal cavity of GF mice with small amounts of individual UV-inactivated bacteria, in addition to HSA and CT. Inoculation of GF mice with S. sciuri or B. clausii, which have high Nod2-stimulatory activity, enhanced the adjuvant activity of CT, whereas inoculation with S. gallinarum or Escherichia coli did not ( Fig. 6f and Supplementary Fig. 13 ). S. sciuri enhanced the adjuvant activity of CT in GF WT mice but not in GF Nod2 −/− mice (Fig. 6g) . Taken together, these results indicate that nasal bacteria promote the adjuvant activity of CT through Nod2 in the nasal cavity.
DISCUSSION
There is mounting evidence that the microbiota has a critical role in the development and function of the host immune system, including the development of T H 17 cells, regulatory T (T reg ) cells and IgA-producing B cells 30, 31 . Furthermore, the microbiota can influence the immune response to viral and bacterial infections 32, 33 . A notable finding of our studies is the role of the microbiota and Nod2 in the regulation of the adjuvant activity of CT. MDP, the Nod2 agonist, was originally identified as the active component of complete Freund's adjuvant and is sufficient for eliciting adjuvant activity 34 . MDP is predominantly a T H 2-polarizing adjuvant, but it enhances T H 1 and T H 2 immune responses in the presence of TLR agonists [19] [20] [21] . Thus, the ability of CT to promote T H 2-skewed humoral immunity could be explained, at least partly, by MDP-induced immune responses via Nod2. Administration of MDP in the nasal cavity of GF mice was sufficient for CT to elicit adjuvant activity. Furthermore, the adjuvant activity of CT was restored in WT but not in Nod2 −/− GF mice colonized with nasal bacteria producing MDP. Collectively, these results indicate that the presence of Nod2-stimulatory bacteria colonizing the nasal cavity is critical for the adjuvant activity of CT. However, it is possible that the adjuvant activity of CT also involves stimulation via the TLRs, as MDP promotes broader immune responses in the presence of TLR agonists [19] [20] [21] . In contrast to the results observed for immunization via the nasal and oral routes, we found no role of the microbiota and Nod2 in the adjuvanticity of CT via the intraperitoneal immunization route. Because the intraperitoneal cavity is considered to be free of bacteria, the results suggest that the microbiota may not be essential for the adjuvanticity of CT; however, the microbiota enhances the adjuvant ability of CT via Nod2 stimulation. This function is important in mucosal surfaces where there are abundant symbiotic bacteria producing Nod2 ligands, including the nasal and gastrointestinal cavities, but not in the peritoneum, which is devoid of bacteria. Additionally, it is possible that small amounts of microbial molecules present in the CT preparation may contribute to the adjuvanticity npg of CT after intraperitoneal immunization, because higher doses of CT are typically used to induce systemic adjuvant activity. Mononuclear phagocytes, including DCs, are critical cellular targets of CT to mediate its adjuvant activity in vivo 3, 6, 7 . In accord with these findings, we found that Nod2 deficiency in CD11c + cells impaired the ability of CT to promote the production of antigen-specific IgG after intranasal immunization. Thus, the adjuvanticity of CT may be explained by its ability to stimulate MDP-mediated immune responses in CD11c + phagocytes such as DCs. Consistent with this notion, stimulation of DCs with CT enhanced MDP-induced cytokine responses through a cAMP-and PKA-dependent mechanism. CT enhanced MDP-induced IL-6, IL-23 and IL-12p40 production in DCs. However, the MDP-induced immune responses that are critical for the adjuvant activity of CT remain unclear. In models of systemic immunization, Nod2 stimulation by MDP induces tumor necrosis factor (ligand) superfamily, member 4 (Tnfsf4; also called OX40 ligand), which is important for T H 2 cell-oriented acquired immunity 35, 36 . In conjunction with IL-21, IL-6 promotes optimal T FH responses and development of germinal center B cells 26, 27 . IL-12 facilitates the differentiation of T FH cells, which is accompanied by an increase in production of IL-21, the chemokine receptor CXCR5 and the T cell co-stimulator ICOS, and promotes antibody production 37, 38 . However, IL-12 and IL-17 are dispensable for the adjuvant activity induced by CT after intranasal immunization 13 . Thus, it is probable that the ability of CT to induce adjuvant activity involves multiple cytokines or activities that remain to be identified. Because both CT and cAMP increased the expression of Nod2 mRNA in DCs, the ability of CT to induce Nod2 expression in DCs may explain, at least in part, the enhancement of MDP-mediated immune responses induced by CT.
One implication of our results is that the microbiota has a role in immune responses induced by immunization with adjuvants. There is evidence of reduced efficacy of humoral immune responses induced by oral vaccines in developing countries, as compared to that in industrialized countries [39] [40] [41] . Although the reasons for the reduced efficacy of vaccines in developing countries are probably complex, the wide variation in antigen-specific antibody responses cannot be explained solely by nutritional differences [42] [43] [44] . Given that the composition of the microbiota in each individual is normally stable throughout life but highly variable among individuals 45 , it is possible that the microbiota impacts the effectiveness of vaccines 40, 46 . Similarly, changes in the microbiota that occur during the life time of an individual, including antibiotic treatment, infection or subtle changes during aging 22, 40, 45 , may contribute to individual variability and efficacy of vaccination. Consistent with this notion, probiotics can influence immune responses induced by vaccines in animal models 47 . We found that the microbiota can enhance the adjuvant activity of CpG in the nasal cavity, indicating that the ability of the microbiota to regulate adjuvanticity is not limited to CT. Similarly, TLR5 recognition of the microbiota contributes to antibody responses in response to parenteral influenza vaccination 48 . TLR5-mediated recognition of the microbiota regulated IgG responses in unadjuvanted vaccines, but not those induced by alum or attenuated viral vaccines 48 . In the unadjuvanted influenza subunit vaccines, the microbiota appears to provide adjuvant activity via TLR5 stimulation 48 . In contrast, the adjuvanticity of CT in the nasal cavity is enhanced by the presence of bacteria producing Nod2 agonists and involves increased Nod2 activation in CD11c + phagocytes. Collectively, these studies suggest that the microbiota can influence humoral immune responses to vaccination via different mechanisms. Although more studies are needed, our studies suggest that environmental and genetic factors that affect the composition of the microbiota may be important factors in determining the capacity of mucosal vaccines to develop protective immunity. Furthermore, understanding the microbial populations and factors that regulate the immune responses to vaccines may provide insight for the development of more effective vaccination protocols.
METHODS
Methods and any associated references are available in the online version of the paper. 
